DGAP-News

MOLOGEN AG: Patient enrollment completed for IMPULSE study with immunotherapy MGN1703 in lung cancer (news with additional features) - Seite 2

Furthermore, MGN1703 is also being investigated in phase I study in HIV
(TEACH). The recruitment ended in September 2015 and topline results are
expected in the first half of 2016.

For more information on the trials IMPACT, IMPALA and TEACH please visit
www.clinicaltrials.gov.

IMPULSE small cell lung cancer study
The trial titled "Randomized Clinical Study of Maintenance Therapy with
Immunomodulator MGN1703 in patients with Extensive Disease Small Cell Lung
Cancer after Platinum-Based First-Line Therapy" (IMPULSE study) has overall
survival as the primary endpoint and compares MGN1703 versus best standard
of care. To date, the study has recruited 101 patients who are suffering
from extensive disease small cell lung cancer (SCLC) and whose tumors have
responded after four cycles of standard first line therapy with
chemotherapeutics. Patients in the experimental arm receive treatment with
MGN1703 until renewed progression of the cancer disease.

Small cell lung cancer (SCLC)
Lung cancer is one of the most common cancer diseases. The two main types
are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
SCLC is a fast-growing type of lung cancer that usually spreads more
quickly than NSCLC.

In the US the estimated number of new lung cancer cases per year is around
230,000 (228,000) and in Europe more than 400,000 (410,000). The estimated
number of deaths per year is around 160,000 in the US and more than 350,000
in Europe. The proportion of small cell lung cancer is approximately 15-20%
of all lung cancer cases.

When first diagnosed, approx. 60-80% of the SCLC-patients have already
distant metastases or extensive local involvement. This advanced stage is
called "extensive disease". The prognosis for extensive disease SCLC is
still very poor: median overall survival is less than 12 months and only
few patients survive for more than two years. Thus, there is a high unmet
medical need for new treatment options.

ABC Group ("Aktion Bronchialkarzinom e.V.")
The ABC Group is an association of more than 60 clinics and oncologists in
Germany. The group members have been involved in clinical studies for 13
years with the aim to optimize therapies for patients with lung cancer and
contribute to improving the lives of patients. A well-organized dialog
among the specialists ensures that studies are carried out in accordance
with most modern insights.

MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN that
broadly activates the immune system. This activation can be utilized to